Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 May 27:5:F1000 Faculty Rev-1019.
doi: 10.12688/f1000research.8265.1. eCollection 2016.

Diabetic macular edema: it is more than just VEGF

Michael A Singer  1 , Daniel S Kermany  2 , Jana Waters  3 , Michael E Jansen  3 , Lyndon Tyler  3
Affiliations
Review

Diabetic macular edema: it is more than just VEGF

Michael A Singer et al. F1000Res. .

Abstract

Diabetic macular edema is a serious visual complication of diabetic retinopathy. This article reviews the history of previous and current therapies, including laser therapy, anti-vascular endothelial growth factor agents, and corticosteroids, that have been used to treat this condition. In addition, it proposes new ways to use them in combination in order to decrease treatment burden and potentially address other causes besides vascular endothelial growth factor for diabetic macular edema.

Keywords: Diabetic macular edema; Laser photocoagulation; VEGF; macular edema.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Michael A. Singer has served as a researcher for Allergan, Genentech, Regeneron, Ampio, Aerpio, Santen, Neurotech, and Optos; a consultant for Allergan, Genentech, Ampio, and Aerpio; and a speaker for Allergan, Genentech, Regeneron, and Ampio.

No competing interests were disclosed.

References

    1. Moss SE, Klein R, Klein BE: The 14-year incidence of visual loss in a diabetic population. Ophthalmology. 1998;105(6):998–1003. 10.1016/S0161-6420(98)96025-0 - DOI - PubMed
    1. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985;103(12):1796–806. 10.1001/archopht.1985.01050120030015 - DOI - PubMed
    1. Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, et al. : Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064–1077.e35. 10.1016/j.ophtha.2010.02.031 - DOI - PMC - PubMed
    1. Nguyen QD, Brown DM, Marcus DM, et al. : Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789–801. 10.1016/j.ophtha.2011.12.039 - DOI - PubMed
    1. Rajendram R, Fraser-Bell S, Kaines A, et al. : A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol. 2012;130(8):972–9. 10.1001/archophthalmol.2012.393 - DOI - PubMed

LinkOut - more resources